Pulmonary fibrosis is a complex, heterogeneous, and often fatal disease characterized by the progressive destruction of lung tissue and the formation of fibrotic scars. It is associated with limited therapeutic options, and its pathogenesis involves multiple cellular and molecular mechanisms. Recent research has identified new pathogenic mechanisms that contribute to the initiation and progression of fibrosis in various contexts. A deeper understanding of these mechanisms is crucial for developing effective treatments. Pulmonary fibrosis can result from various causes, including idiopathic pulmonary fibrosis (IPF), viral infections, radiotherapy, chemotherapy, and environmental toxins. It is also observed in some bone marrow transplant recipients and individuals with chronic inflammatory diseases. The only effective treatment for progressive lung fibrosis is lung transplantation. Tissue repair is a fundamental biological process that allows for the replacement of damaged cells, but when dysregulated, it can lead to fibrosis. The wound healing process involves several stages, including clotting, inflammation, fibroblast migration and proliferation, and tissue remodeling. In the context of pulmonary fibrosis, dysregulation at any stage can lead to fibrotic scarring. Inflammation plays a significant role in the progression of pulmonary fibrosis. Proinflammatory mediators such as TNF, IL-1β, and IL-17A contribute to the development and progression of fibrosis. These mediators can promote fibroblast activation, ECM deposition, and the recruitment of inflammatory cells. However, the role of inflammation in fibrosis varies, with some forms of the disease being driven by fibrotic processes rather than inflammation. The Wnt-β-catenin signaling pathway is constitutively active in some alveolar type II cells in IPF and is involved in the pathogenesis of pulmonary fibrosis. The integrin α3β1 and Wnt-β-catenin pathways both contribute to the development of pulmonary fibrosis. Epigenetic changes in fibroblasts, such as DNA methylation, can also contribute to the pathogenesis of fibrosis by preventing fibroblasts from returning to a resting state. Th2 responses and IL-13 are important in the development of pulmonary fibrosis. IL-13 can directly activate fibroblasts and promote fibrosis. The IL-13 signaling pathway is a dominant inducer of Th2-dependent fibrosis in several chronic lung diseases. IL-13 also plays a role in the development of fibrosis by promoting the production of profibrotic mediators. Chemokines play a critical role in recruiting leukocytes and fibroblasts to the lung, contributing to the development of fibrosis. Blocking or genetically deleting certain chemokines can provide protection against fibrosis. However, not all chemokines promote fibrosis; some, such as CXCL10 and CXCL11, can inhibit fibrosis by preventing fibroblast recruitment and promoting the production of antifibrotic cytokPulmonary fibrosis is a complex, heterogeneous, and often fatal disease characterized by the progressive destruction of lung tissue and the formation of fibrotic scars. It is associated with limited therapeutic options, and its pathogenesis involves multiple cellular and molecular mechanisms. Recent research has identified new pathogenic mechanisms that contribute to the initiation and progression of fibrosis in various contexts. A deeper understanding of these mechanisms is crucial for developing effective treatments. Pulmonary fibrosis can result from various causes, including idiopathic pulmonary fibrosis (IPF), viral infections, radiotherapy, chemotherapy, and environmental toxins. It is also observed in some bone marrow transplant recipients and individuals with chronic inflammatory diseases. The only effective treatment for progressive lung fibrosis is lung transplantation. Tissue repair is a fundamental biological process that allows for the replacement of damaged cells, but when dysregulated, it can lead to fibrosis. The wound healing process involves several stages, including clotting, inflammation, fibroblast migration and proliferation, and tissue remodeling. In the context of pulmonary fibrosis, dysregulation at any stage can lead to fibrotic scarring. Inflammation plays a significant role in the progression of pulmonary fibrosis. Proinflammatory mediators such as TNF, IL-1β, and IL-17A contribute to the development and progression of fibrosis. These mediators can promote fibroblast activation, ECM deposition, and the recruitment of inflammatory cells. However, the role of inflammation in fibrosis varies, with some forms of the disease being driven by fibrotic processes rather than inflammation. The Wnt-β-catenin signaling pathway is constitutively active in some alveolar type II cells in IPF and is involved in the pathogenesis of pulmonary fibrosis. The integrin α3β1 and Wnt-β-catenin pathways both contribute to the development of pulmonary fibrosis. Epigenetic changes in fibroblasts, such as DNA methylation, can also contribute to the pathogenesis of fibrosis by preventing fibroblasts from returning to a resting state. Th2 responses and IL-13 are important in the development of pulmonary fibrosis. IL-13 can directly activate fibroblasts and promote fibrosis. The IL-13 signaling pathway is a dominant inducer of Th2-dependent fibrosis in several chronic lung diseases. IL-13 also plays a role in the development of fibrosis by promoting the production of profibrotic mediators. Chemokines play a critical role in recruiting leukocytes and fibroblasts to the lung, contributing to the development of fibrosis. Blocking or genetically deleting certain chemokines can provide protection against fibrosis. However, not all chemokines promote fibrosis; some, such as CXCL10 and CXCL11, can inhibit fibrosis by preventing fibroblast recruitment and promoting the production of antifibrotic cytok